NCT03368092View on ClinicalTrials.gov

Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma

PHASE3RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

March 4, 2019

Primary Completion Date

September 1, 2027

Study Completion Date

December 1, 2027

Conditions
Multiple TraumaRespiratory Distress Syndrome, Adult
Interventions
DRUG

Dornase Alfa Inhalant Solution [Pulmozyme]

Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.

DRUG

Placebos

NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.

Trial Locations (1)

67000

RECRUITING

University Hospital, Strasbourg, france, Strasbourg

All Listed Sponsors
lead

University Hospital, Strasbourg, France

OTHER